Pfizer Inc. (NYSE:PFE) Shares Purchased by Knott David M Jr

Knott David M Jr grew its stake in Pfizer Inc. (NYSE:PFE) by 13.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 254,537 shares of the biopharmaceutical company’s stock after purchasing an additional 30,000 shares during the period. Pfizer comprises about 2.4% of Knott David M Jr’s investment portfolio, making the stock its 7th biggest position. Knott David M Jr’s holdings in Pfizer were worth $6,753,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. United Bank raised its position in Pfizer by 3.7% in the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock worth $1,030,000 after purchasing an additional 1,277 shares in the last quarter. Tradition Wealth Management LLC grew its stake in Pfizer by 4.5% during the third quarter. Tradition Wealth Management LLC now owns 25,358 shares of the biopharmaceutical company’s stock worth $734,000 after buying an additional 1,099 shares during the last quarter. Erste Asset Management GmbH acquired a new stake in shares of Pfizer during the third quarter worth approximately $16,776,000. Benjamin Edwards Inc. raised its stake in shares of Pfizer by 1,399.9% in the third quarter. Benjamin Edwards Inc. now owns 240,258 shares of the biopharmaceutical company’s stock valued at $6,953,000 after acquiring an additional 224,240 shares during the last quarter. Finally, Ascent Group LLC boosted its holdings in shares of Pfizer by 23.3% in the 3rd quarter. Ascent Group LLC now owns 62,712 shares of the biopharmaceutical company’s stock worth $1,815,000 after acquiring an additional 11,867 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on PFE. Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. UBS Group lowered their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. Citigroup decreased their price objective on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Finally, Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. One research analyst has rated the stock with a sell rating, seven have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to MarketBeat, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Stock Up 0.6 %

NYSE:PFE opened at $25.36 on Tuesday. The stock has a 50-day simple moving average of $26.05 and a 200 day simple moving average of $26.88. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a market cap of $143.80 billion, a PE ratio of 17.98, a PEG ratio of 0.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period last year, the company earned $0.10 earnings per share. The firm’s revenue was up 24.7% compared to the same quarter last year. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Transactions at Pfizer

In related news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the acquisition, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.